Skip to content

May 2025

A research survey is the first to evaluate patient perspectives and considerations regarding the application of AI in the diagnosis of IRDs.

Researchers at the University College London, Institute of Ophthalmology, and Moorfields Eye Hospital, NHS Foundation Trust, UK, reported a study indicating that large disparities of… Read More »A research survey is the first to evaluate patient perspectives and considerations regarding the application of AI in the diagnosis of IRDs.

Clinical research on patients with infantile nystagmus syndrome (INS), across several inherited ocular diseases, may provide significant support for counselling and on-going clinical trials.   

Clinical researchers at the Department of Ophthalmology and the Vision Centre of Excellence, Akron Children’s Hospital, Ohio, have reported a molecular diagnostic rate of 41.5%… Read More »Clinical research on patients with infantile nystagmus syndrome (INS), across several inherited ocular diseases, may provide significant support for counselling and on-going clinical trials.   

Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.

Ashvattha Therapeutics, based in Redwood City, California, have announced positive interim Phase 2 results for migaldendranib (MGB) and hydroxyl dendrimer, aimed to treat retinal vascular… Read More »Ashvattha Therapeutics has announced positive Phase 2 results for subcutaneous migaldendranib, delivered via a hydroxyl dendrimer for retinal vascular disease.

New study on a genome-wide association of central serous chorioretinopathy (CSC), varicose veins and glaucoma identifies a missense variant in PTPRB gene.

Researchers at the Institute for Molecular Medicine Finland (FIMM), University of Helsinki, and the Massachusetts Eye and Ear and Broad Institute of MIT and Harvard,… Read More »New study on a genome-wide association of central serous chorioretinopathy (CSC), varicose veins and glaucoma identifies a missense variant in PTPRB gene.

Natural history of PCARE-associated retinopathy highlights genetics, clinical characteristics and time-to-event curves for development of atrophy. 

Clinical researchers at the Sorbonne Université, INSERM, CNRS, Institut de la Vision and  the Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, Paris, have reported PCARE-associated retinopathy… Read More »Natural history of PCARE-associated retinopathy highlights genetics, clinical characteristics and time-to-event curves for development of atrophy. 

Opus Genetics Inc., has announced 12-month summary results for OPGx-LCA5 – an experimental gene therapy treatment of LCA5 retinal disease. 

Opus Genetics Inc., (NASDAQ: IRD), based in Raleigh, North Carolina, has announced the one-year summary results from adult patients treated in an ongoing Phase 1/2… Read More »Opus Genetics Inc., has announced 12-month summary results for OPGx-LCA5 – an experimental gene therapy treatment of LCA5 retinal disease.